该行认为集团是药物研发业务的全球领导者，正乘着中国CRO行业的增长趋势发展;集团在维持药物研 发领导地位同时，亦正扩展至下游的后期临床开发和商业化生产，并涉足生物制剂领域。 花旗指，集团将成为客户需求复苏的领先指标，并为未来收入增长提供更清晰指引，可能导致今财年指 引高于市场共识，并推动股价正面重估。花旗对集团今年每股盈利的预测较市场共识高出4%。 花旗发布研报称，对康龙化成（300759）(03759)展开为期90天的正面催化观察，主要催化剂为集团即 将公布去年全年业绩、订单增长加速下集团今年的指引更乐观。花旗予康龙化成H股"买入"评级，目标 价45港元. ...

花旗指，集团将成为客户需求复苏的领先指标，并为未来收入增长提供更清晰指引，可能导致今财年指 引高于市场共识，并推动股价正面重估。花旗对集团今年每股盈利的预测较市场共识高出4%。 该行认为集团是药物研发业务的全球领导者，正乘着中国CRO行业的增长趋势发展; 集团在维持药物研 发领导地位同时，亦正扩展至下游的后期临床开发和商业化生产，并涉足生物制剂领域。 智通财经APP获悉，花旗发布研报称，对康龙化成(03759)展开为期90天的正面催化观察，主要催化剂为 集团即将公布去年全年业绩、订单增长加速下集团今年的指引更乐观。花旗予康龙化成H股"买入"评 级，目标价45港元. ...

花旗予康龙化成H股"买入"评级，目标价为45港元；认为集团是药物研发业务的全球领导者，正乘着中 国CRO行业的增长趋势发展；集团在维持药物研发领导地位同时，亦正扩展至下游的后期临床开发和 商业化生产，并涉足生物制剂领域。 花旗发表研报指，对康龙化成展开为期90天的正面催化观察，主要催化剂为集团即将公布去年全年业 绩、订单增长加速下集团今年的指引更乐观。花旗指，集团将成为客户需求复苏的领先指标，并为未来 收入增长提供更清晰指引，可能导致今财年指引高于市场共识，并推动股价正面重估。 ...

Core Viewpoint - Shenzhen's Industrial and Information Technology Bureau has issued the "Shenzhen 'Artificial Intelligence +' Advanced Manufacturing Action Plan (2026-2027)", focusing on accelerating innovation and transformation in drug research and development, cell and gene therapy, and precision medical services [1] Group 1: Action Plan Objectives - The plan aims to promote technological innovation in key areas such as drug target discovery and validation, drug design, high-throughput drug screening, DNA-encoded compound library screening, computer-aided drug design, virtual screening, and gene locus screening related to drug therapy [1] - It supports the establishment of major platforms for AI-driven drug research and development, enhancing the integration of technological resources [1] Group 2: AI and Biotechnology Integration - The initiative emphasizes the deep integration of artificial intelligence and biotechnology (AI+BT) to accelerate advancements in the sector [1]

Core Viewpoint - The company has established an AI professional team and server infrastructure to enhance innovation in drug development, process design, intelligent manufacturing, and quality control [1] Group 1: AI Integration - The company is accelerating the application of AI across various stages of its operations, including drug research and development [1] - There is an ongoing effort to collaborate with leading external AI technology platforms and research institutions to promote deep integration and intelligent upgrades of AI technology throughout the company's entire industry chain [1]

Core Viewpoint - The implementation of the negative list for data export in free trade zones presents both opportunities and challenges for enterprises, facilitating cross-border data flow while ensuring compliance with regulations [1] Group 1: Policy Implementation and Impact - The Shanghai Free Trade Zone (FTZ) has initiated the first national practice exchange event for the negative list of data export, involving various departments and over 50 key enterprises [1] - The negative list allows enterprises to report data export activities after usage, eliminating prior approval processes and potentially exempting them from evaluations or filings [2] - The introduction of the negative list has significantly reduced compliance costs for enterprises, with thresholds for sensitive personal information raised from 10,000 to 100,000 individuals [2] Group 2: Support and Guidance for Enterprises - A data cross-border service center has been established in the Shanghai FTZ, conducting nearly 20 policy briefings and providing one-on-one consultations for over 1,000 enterprises [3] - An expert group has been formed to support data cross-border facilitation, including professionals from various organizations to assist enterprises in expanding overseas markets [3] - The city and district data cross-border teams are continuously updating operational guidelines and providing professional training to better address enterprise needs [3] Group 3: Events and Activities - During the National Cybersecurity Awareness Week, seven district-level activities will be held, including policy practice exchanges and cybersecurity competitions [4]

Core Viewpoint - Bayer and Tsinghua University have signed the sixth phase of their strategic research cooperation agreement, aiming to enhance the translation of basic research into new drug development across multiple key areas such as oncology, cardiovascular and renal diseases, neurology, rare diseases, and immunology [1][3]. Group 1: Research Collaboration - Bayer will continue to fund joint research projects for the next three years and reward Tsinghua University scientists who make significant contributions in life sciences and drug innovation [2]. - Since 2009, Bayer has collaborated with Tsinghua University on 75 joint research projects, resulting in 15 co-authored papers published in renowned international academic journals [3]. - The establishment of the "Bayer Research Transformation Fund" in 2022 has supported 9 projects in the past three years, further enhancing the translation of early research outcomes [3]. Group 2: Innovation and Development - Bayer's collaboration with Tsinghua University is seen as a model for cooperation between multinational pharmaceutical companies and local academic institutions in China, contributing to significant advancements in scientific research and drug development [4]. - The partnership aims to address global health challenges and accelerate the conversion of basic research into drug applications, marking an important milestone in their long-term strategic cooperation [4]. - Bayer emphasizes its commitment to local research collaboration and supports the transformation of original innovations and new drug development in China [5]. Group 3: Local Ecosystem Engagement - As China becomes a major source of biotechnological innovation, Bayer is actively integrating into the local innovation ecosystem and exploring open innovation with Chinese partners [6]. - Bayer Co.Lab, set to open in September 2024, aims to empower 10 to 15 local startups focusing on cutting-edge innovations in oncology, cardiovascular and renal diseases, and cell and gene therapies [6]. - Bayer has entered a global licensing agreement with a Chinese biotechnology company for a selective oral small molecule PRMT5 inhibitor targeting MTAP-deficient tumors, with the first patient already recruited for Phase I clinical trials [6].